Beurs gesloten -
Hong Kong S.E.
10:08:20 26-04-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
10,74
HKD
|
+4,88%
|
|
+16,23%
|
-44,75%
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Marktkapitalisatie
1 |
18.711
|
64.649
|
56.686
|
57.119
|
35.947
|
23.066
|
-
|
-
|
Bedrijfswaarde
1 |
18.402
|
62.115
|
53.714
|
52.363
|
33.930
|
20.466
|
21.397
|
21.944
|
K/w-verhouding
|
-24,9
x
|
-23,4
x
|
-59,1
x
|
-
|
-
|
-5,72
x
|
-9,71
x
|
-15,5
x
|
Dividendrendement
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Marktkapitalisatie/omzet
|
24,1
x
|
40,5
x
|
14,1
x
|
39,3
x
|
23,9
x
|
12,6
x
|
7,26
x
|
6,37
x
|
Bedrijfswaarde/omzet
|
23,7
x
|
38,9
x
|
13,3
x
|
36
x
|
22,6
x
|
11,2
x
|
6,74
x
|
6,06
x
|
Bedrijfswaarde/EBITDA
|
-23,5
x
|
-41,7
x
|
-127
x
|
-21,7
x
|
-15,7
x
|
-11,2
x
|
-19,1
x
|
-21,6
x
|
Bedrijfswaarde/FCF
|
-9,3
x
|
-30,5
x
|
-38
x
|
-24,1
x
|
-12
x
|
-8,32
x
|
-21,7
x
|
-14,4
x
|
FCF Yield
|
-10,8%
|
-3,28%
|
-2,63%
|
-4,14%
|
-8,35%
|
-12%
|
-4,6%
|
-6,93%
|
Price to Book
|
6,26
x
|
7,14
x
|
5,17
x
|
-
|
-
|
1,35
x
|
1,61
x
|
1,64
x
|
Aantal aandelen (in duizenden)
|
784.147
|
872.496
|
910.757
|
982.872
|
985.011
|
984.908
|
-
|
-
|
Referentieprijs
2 |
23,86
|
47,81
|
47,26
|
42,83
|
17,67
|
9,942
|
9,942
|
9,942
|
Datum van publicatie
|
2/03/20
|
26/02/21
|
25/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Omzet
1 |
775,1
|
1.595
|
4.025
|
1.453
|
1.503
|
1.834
|
3.176
|
3.620
|
EBITDA
1 |
-783,5
|
-1.490
|
-422
|
-2.417
|
-2.168
|
-1.823
|
-1.122
|
-1.015
|
Bedrijfsresultaat (EBIT)
1 |
-747,3
|
-1.636
|
-558,3
|
-2.666
|
-2.457
|
-1.851
|
-1.111
|
-394,1
|
Operationele Marge
|
-96,41%
|
-102,59%
|
-13,87%
|
-183,41%
|
-163,55%
|
-100,91%
|
-34,98%
|
-10,89%
|
Resultaat voor belastingen (EBT)
1 |
-763,1
|
-1.672
|
-595
|
-2.677
|
-2.492
|
-1.967
|
-883
|
-433
|
Nettowinst (verlies)
1 |
-747,4
|
-1.669
|
-720,9
|
-2.388
|
-2.283
|
-1.719
|
-801,5
|
-499,5
|
Nettomarge
|
-96,43%
|
-104,62%
|
-17,91%
|
-164,3%
|
-151,97%
|
-93,71%
|
-25,24%
|
-13,8%
|
WPA
2 |
-0,9600
|
-2,040
|
-0,8000
|
-
|
-
|
-1,737
|
-1,024
|
-0,6399
|
Free Cash Flow
1 |
-1.979
|
-2.037
|
-1.414
|
-2.170
|
-2.833
|
-2.460
|
-984,5
|
-461,5
|
FCF-marge
|
-255,28%
|
-127,71%
|
-35,14%
|
-149,31%
|
-188,58%
|
-134,13%
|
-31%
|
-12,75%
|
Kasstroomconversie (ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (nettowinst)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per aandeel
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
2/03/20
|
26/02/21
|
25/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
1 |
309
|
2.534
|
2.972
|
4.756
|
2.017
|
2.600
|
1.669
|
1.123
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.979
|
-2.037
|
-1.414
|
-2.170
|
-2.833
|
-2.460
|
-985
|
-462
|
ROE (netto-inkomsten/eigen vermogen)
|
-23,6%
|
-37,7%
|
-10,4%
|
-32,7%
|
-27,3%
|
-25,8%
|
-12,8%
|
-6,78%
|
ROA (netto-inkomsten/totale activa)
|
-17,1%
|
-26,8%
|
-9,24%
|
-
|
-18,8%
|
-17,9%
|
-9,71%
|
-4,53%
|
Totale activa
1 |
4.360
|
6.228
|
7.802
|
-
|
12.138
|
9.617
|
8.256
|
11.039
|
Nettoactief per aandeel
2 |
3,810
|
6,690
|
9,150
|
-
|
-
|
7,390
|
6,190
|
6,060
|
Cashflow per aandeel
2 |
-0,9100
|
-1,780
|
-0,7200
|
-
|
-
|
-0,9100
|
-0,5700
|
-
|
Capex
1 |
792
|
580
|
772
|
394
|
828
|
586
|
329
|
373
|
Capex/omzet
|
102,13%
|
36,4%
|
19,19%
|
27,1%
|
55,14%
|
31,92%
|
10,36%
|
10,3%
|
Datum van publicatie
|
2/03/20
|
26/02/21
|
25/02/22
|
27/02/23
|
23/02/24
|
-
|
-
|
-
|
Gemiddeld advies Accumuleren Laatste slotkoers
9,942
CNY Gemiddelde koersdoel
22,5
CNY Spread / Gemiddelde doel +126,33% Consensus |
Vaira. 1 jan.
|
Kapi.
|
---|
| -44,75% | 3,18 mld. | | -4,66% | 86,13 mld. | | +1,32% | 39,82 mld. | | -19,27% | 30,42 mld. | | +57,86% | 25,23 mld. | | -17,69% | 11,6 mld. | | -43,00% | 11,51 mld. | | -9,14% | 11,95 mld. | | +5,24% | 8,71 mld. | | -8,42% | 8,12 mld. |
Biofarmaceutica
|